Studying the genetics of leukaemia to find new treatments
Investigations into EVI1 mediated epigenetic modulation in childhood leukaemia
Developing a laboratory model of Wilms tumour to test potential new treatments
In vitro modelling of MYCN-driven poor prognosis Wilms' tumour for assessment of novel therapies
Investigating a new way of delivery drugs to the site of childhood brain tumours
Brain distribution models to select polymer-delivered drugs for the treatment of childhood brain cancers
How do childhood brain tumours start?
Defining the cellular origins of neonatal and paediatric brain tumours
Improving our understanding of the genetics of neuroblastoma
Understanding neuroblastoma heterogeneity: genetic studies of circulating neuroblastoma tumour cells
Developing a blood test to help identify high risk Wilms tumours
Circulating molecular biomarkers for earlier identification of high risk Wilms tumour
Discovering biomarkers in high grade glioma to help find targeted treatments
Identifying the metabolic ‘Achilles Heel’ of childhood brain cancers
Can a carbohydrate restricted diet help treat childhood brain tumours?
In vitro evaluation of the potential of glucose restriction as an adjuvant therapy for paediatric brain tumours
Developing new treatments for high-risk neuroblastoma
Pre-clinical efficacy and biomarker studies of ALK, MAPK and MDM2-p53 inhibitor combinations in neuroblastoma